Baxdrostat: A selective aldosterone synthase inhibitor for resistant hypertension

Le résumé fourni par la source

Resistant hypertension (rHTN) is a high-risk clinical phenotype defined as blood pressure that remains above the target goal (typically 140/90 mmHg) despite the concurrent use of three or more antihypertensive agents of different classes – including a long-acting calcium channel blocker, a RAAS inhibitor, and a thiazide-like diuretic – at maximally tolerated doses.[1,2] The prevalence of rHTN is approximately 11%–16.13% among hypertensive Indian adults.[3] Patients with rHTN face a significantly higher risk of end-organ damage, including stroke, myocardial infarction, and chronic kidney disease (CKD), compared to those with controlled hypertension.[4] While multifactorial, the condition is driven by the interplay between several neurohumoral factors, including increased sympathetic activity and levels of aldosterone, endothelin-1, and vasopressin that lead to excessive fluid volume and persistent hormonal signaling that overrides standard medications.[5,6] This clinical challenge has spurred the development of Baxdrostat, a highly selective inhibitor of aldosterone synthase (CYP11B2). Conventionally, clinicians have used mineralocorticoid receptor antagonists (MRAs) like spironolactone to block aldosterone’s effects. However, MRAs can lead to side effects like gynecomastia or significant hyperkalaemia. Baxdrostat offers a novel approach by selectively inhibiting the synthesis of aldosterone at its source. By targeting CYP11B2 with high precision – sparing the nearly identical CYP11B1 enzyme responsible for cortisol synthesis – Baxdrostat aims to neutralize the hormonal driver of rHTN without inducing adrenal insufficiency.[7,8] The clinical efficacy of Baxdrostat has been established through a series of robust Phase II and Phase III trials focusing on rHTN and CKD [Table 1].Table 1: Summary of clinical efficacy trials evaluating Baxdrostat in hypertension and chronic kidney disease BaxHTN: In this pivotal trial of 796 patients, the 2 mg dose achieved an absolute SBP reduction of 15.7 mmHg from baseline. Nearly 40% of patients reached the target SBP of <130 mmHg[8] Bax24: This study utilized 24-h ambulatory monitoring, demonstrating a 13.9 mmHg placebo-adjusted reduction specifically during night-time hours – a critical period for reducing stroke risk[9] FigHTN: Evaluated patients with Stage 3 or 4 CKD. While it showed an 8.1 mmHg SBP reduction, it also noted significant decreases in albuminuria, suggesting potential renal protection.[10] Baxdrostat has been generally well-tolerated, with a safety profile consistent with its mechanism: Hyperkalemia: Potassium levels >6.0 mmol/L occurred in 1% of the general rHTN population but were significantly higher (4.1%) in the CKD subgroup, requiring closer monitoring in patients with renal impairment Cortisol Safety: No cases of clinically significant adrenocortical insufficiency have been reported, confirming the drug’s high selectivity Common Events: Minor side effects include headache, fatigue, dizziness, nasopharyngitis, and diarrhea.[7-10] Baxdrostat is currently under FDA Priority Review as of March 2026. Following the submission of the Phase III BaxHTN and Bax24 data, a regulatory decision is anticipated in the second quarter of 2026. If approved, it will be the first aldosterone synthase inhibitor available for clinical use.[11] As of 2026, regulatory filings for Baxdrostat are advancing. Research is expanding into its use as a combination therapy (e.g., with dapagliflozin) for CKD and heart failure prevention, where aldosterone-mediated tissue damage is a central concern.[12] Baxdrostat is a promising, first-in-class selective aldosterone synthase inhibitor that effectively lowers blood pressure in resistant hypertension. Its high selectivity and favorable safety profile distinguish it from earlier therapies. Ongoing research will determine its long-term clinical role. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.